Helius Medical Stock Soars 141.42% on PoNS Device Reimbursement

On June 11, 2025, Helius Medical's stock surged by 141.42% in pre-market trading, marking a significant milestone for the company. This dramatic increase can be attributed to several key developments that have bolstered investor confidence in the neurotech firm.

One of the primary drivers behind this surge is the recent authorization of a claim for the PoNS Device by Aetna Healthcare. This approval, which comes at an out-of-network negotiated price of $18,350, represents a significant step forward in expanding third-party payer reimbursement for the PoNS Device. Aetna joins Anthem and United in providing reimbursement for the PoNS Device, which is used to treat balance and gait deficits in patients with multiple sclerosis (MS).

Helius Medical Technologies, Inc. has been actively pursuing broader in-network coverage for the PoNS Device from major commercial payers. The company is also negotiating reimbursement on a case-by-case basis and aims to align commercial payments with the rates currently offered by the VA/DoD at $26,228. This strategic approach is expected to benefit individuals with MS who rely on Medicare for PoNS treatment and support the company's efforts to secure fair and adequate reimbursement by CMS for the PoNS system.

The PoNS Device, a non-implantable, orally applied therapy, delivers neurostimulation through a mouthpiece connected to a controller. It is used in conjunction with physical rehabilitation exercises to improve balance and gait. The device has shown effectiveness in treating gait or balance deficits and reducing the risk of falling in stroke patients in Canada and Australia, where it has received authorization for sale in multiple indications.

Helius Medical Technologies is committed to supporting individuals with MS and other neurologic diseases through its innovative technology platform. The company's focus on neurologic deficits using orally applied technology aims to amplify the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, ultimately improving the lives of patients dealing with neurologic diseases.